EUVIMEDEUVIMED entdecken
Open Access

In vivo pharmacodynamic evaluation of the novel nystatin derivative BSG005 in the invasive candidiasis and invasive pulmonary aspergillosis mouse models

Alexander J Lepak, Justin Massey, Robert Zarnowski iD, Tine K Olesen, Ryley Jones, David R Andes iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.01234-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Alexander J Lepak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Microbial Sensitivity Tests, Invasive Pulmonary Aspergillosis, Disease Models, Animal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nystatin, a polyene, is one of the oldest antifungal drugs with wide in vitro potency. BSG005 is a novel, chemically modified, nystatin-like molecule in development for systemic therapy. We evaluated the pharmacokinetic/pharmacodynamic (PK/PD) relationships and target exposures using in vivo invasive pulmonary aspergillosis (IPA) and invasive candidiasis (IC) infection models for BSG005 against common fungal pathogens including Aspergillus fumigatus , Candida albicans , Candida auris , and Candida glabrata . For each species group, three to four strains were selected. Minimum inhibitory concentration (MIC) testing was done by Clinical Laboratory Standards Institute (CLSI) methods. Single-dose kinetics for BSG005 were performed at four dose levels. The immunosuppressed mouse IPA model was used for A. fumigatus studies. For all Candida studies, we utilized the neutropenic disseminated candidiasis model. We used quantitative PCR to enumerate Aspergillus in the lung and colony forming units (CFU) counts for Candida in the kidney. Treatment results were evaluated based on both area under the concentration-time curve (AUC)/MIC and maximum plasma concentration ( C max )/MIC exposures. The BSG005 MIC was 1 mg/L against all strains. Escalating doses of BSG005 resulted in increased effect and, in general, the dose-response curves within each species were concordant. The median 96-h AUC/MIC associated with net stasis was lowest at 6.08 for C. glabrata . Increasing exposures were needed for same outcome for C. auris at 18.7, C. albicans at 29.3, and A. fumigatus at 102.4. C max /MIC targets for the four groups were 0.22, 0.48, 0.60, and 1.41. BSG005 demonstrated potent activity against a variety of fungal pathogens in the neutropenic mouse models. C max /MIC PK/PD targets were numerically lower than other polyene studies using the same infection models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsMicrobial Sensitivity TestsInvasive Pulmonary AspergillosisDisease Models, AnimalAspergillus fumigatusCandidiasis, InvasiveCandida albicansNystatinAnimalsMiceFemaleCandida glabrataCandida auris

Stichwörter der Autor:innen

AspergillusBSG-005CandidaPK/PDpolyene

Substanzen

Antifungal AgentsNystatin

Autor:innen und Institutionen

  • Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
  • Biosergen AS, Trondheim, Norway.
  • Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, Wisconsin, USA.
  • William S. Middleton Memorial VA Hospital, Madison, Wisconsin, USA.

ORCID-Profile: Robert Zarnowski, David R Andes

Zitieren

APA

Lepak, A. J., Massey, J., Zarnowski, R., Olesen, T. K., Jones, R., & Andes, D. R. (2024). In vivo pharmacodynamic evaluation of the novel nystatin derivative BSG005 in the invasive candidiasis and invasive pulmonary aspergillosis mouse models. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01234-24

Vancouver

Lepak AJ, Massey J, Zarnowski R, Olesen TK, Jones R, Andes DR. In vivo pharmacodynamic evaluation of the novel nystatin derivative BSG005 in the invasive candidiasis and invasive pulmonary aspergillosis mouse models. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01234-24

BibTeX
@article{Lepak2024,
  author = {Lepak, Alexander J and Massey, Justin and Zarnowski, Robert and Olesen, Tine K and Jones, Ryley and Andes, David R},
  title = {In vivo pharmacodynamic evaluation of the novel nystatin derivative BSG005 in the invasive candidiasis and invasive pulmonary aspergillosis mouse models},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01234-24}
}
Kostenlos starten →